Double-Filtration Plasmapheresis plus IFN for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy: Early Viral Dynamics

Soo Ryang Kim, Susumu Imoto, Masatoshi Kudo, Keiji Mita, Miyuki Taniguchi, Ke Ih Kim, Noriko Sasase, Ikuo Shoji, Motoko Nagano-Fujii, Ahmed El-Shamy, Hak Hotta, Tomoyuki Nagai, Yoshiaki Nagata, Yoshitake Hayashi

**Key Words**
- Chronic hepatitis C
- Double-filtration plasmapheresis
- Early viral dynamics
- Genotype 1b
- High viral load
- Interferon β
- Non-sustained virological responder
- Peginterferon plus ribavirin combination therapy

**Abstract**
Double-filtration plasmapheresis (DFPP) was approved in Japan in April 2008 for the retreatment of chronic hepatitis C patients with genotype 1b and high viral loads, whose hepatitis C virus was not eradicated by earlier IFN therapy or by pegylated IFN plus ribavirin (PEG-IFN/RBV) combination therapy. In this study, we assessed the early viral dynamics of 9 patients with non-sustained virological response to the combination therapy. The overall viral dynamics of DFPP plus IFN treatment with or without RBV for 4 weeks showed a reduction of $\geq 1$ log in the viral load in 22% (2 of 9 patients), 55.6% (5/9), 77.8% (7/9) and 77.8% (7/9) at 24 h, 1, 2 and 4 weeks after the start of treatment. By contrast, DFPP plus consecutive intravenous IFN-β for 4 weeks reduced the viral load by $\geq 1$ log it 33% (2/6), 50% (3/6), 83.3% (5/6) and 83.3% (5/6) at 24 h, 1, 2 and 4 weeks. The viral load declined by $\geq 2$ log in 50% (3/6) at 4 weeks after the start of treatment. DFPP plus consecutive intravenous IFN-β for 4 weeks is a promising treatment for non-sustained virological response patients.

**Introduction**
Hepatitis C virus (HCV) infection is the major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) in industrialized countries. HCV infection is manageable, however, and its complications can be prevented by antiviral therapy [1, 2]. Currently, the most effective treatment for chronic HCV infection is based on pegylated interferon plus ribavirin (PEG-IFN/RBV) combination therapy [3]. Nonetheless, sustained...
virological response (SVR) rates for those infected with the most resistant genotypes (HCV-1a and HCV-1b) still hover around 50% [3, 4].

To surmount this SVR rate with combination therapy, several trials have been undertaken, two of which are: (1) retreatment with combination therapy and (2) double-filtration plasmapheresis (DFPP). By the protocol-defined primary analysis of the former, the SVR rate has been 16% at most, even for a 72-week induction group [5].

The use of DFPP [approved in Japan in April 2008 for the retreatment of chronic hepatitis C (CHC) patients with genotype 1b and high viral loads] together with IFN administration has produced a substantial reduction in the viral load during the early stages of treatment and has effected a high SVR [6], suggesting that this treatment is a new modality for CHC patients in difficult-to-treat states. In this study, we used DFPP plus IFN to enhance the efficacy of the treatment of CHC patients whose HCV was not eradicated by earlier PEG-IFN/RBV combination therapy, and we assessed early viral dynamics associated with SVR.

**Patients and Methods**

**Patients**

Nine patients (aged 43–66 years) whose HCV had not been eradicated by earlier PEG-IFNα-2b plus RBV combination therapy carried out between 2008 and 2009 were enrolled in this study. The patients were divided into 2 groups: partial responders (PR; relapse after the end of therapy) and non-responders (NR; no disappearance of HCV RNA during therapy). All the patients were confirmed to be HCV RNA positive with high transaminase levels persisting for 6 months or longer, and with HCV RNA genotypes 1a and 4, and high viral loads [7, 8] together with IFN resistance.

**DFPP and Blood Collection**

Blood collected from the peripheral vein for DFPP by a Plasmaplo™ OP-18W filter (Asahi Kasei Medical, Tokyo, Japan) was separated into plasma and cell components. The virus was then removed from the plasma by a second filter (Cascadeflo™ EC-50W; Asahi Kasei Medical) of an average pore size of 30 nm. For each session, the total volume of treated plasma was 50 ml/kg; the number of sessions was 5 over 2 weeks, and the time of DFPP, based on the reduced plasma fibrinogen levels during DFPP, was decided by the physicians and as required by the patients.

**Types of IFN for 4 Weeks with DFPP**

During DFPP, the patients were treated with different kinds of IFN: patient 1 with PEG-IFNα-2b plus RBV for 4 weeks; patients 2 and 3 with IFN-β 3 MU twice daily for 2 weeks and PEG-IFNα-2a plus RBV for 2 weeks; patients 4 and 9 with IFN-β 3 MU twice daily for 2 weeks and IFN-β 6 MU daily for 2 weeks; patients 5 with IFN-β 3 MU twice daily for 10 days and IFN-β 6 MU daily for 18 days, and patients 6, 7 and 8 with IFN-β 3 MU twice daily for 4 weeks. The dose of PEG-IFNα-2b was 1.5 μg/kg and 180 μg of α-2a per week. The RBV dose was 800 mg/day with α-2b and 600–800 mg/day with α-2a. After DFPP plus IFN treatment for 4 weeks, all patients were scheduled to receive PEG-IFN/RBV combination therapy (patient 1: PEG-IFNα-2b 1.5 μg/kg per week plus RBV 800 mg/day; patients 2–9: PEG-IFNα-2a 180 μg per week plus RBV 600–800 mg/day).

**Amino Acid Substitutions in the Core Region (aa 30 and aa 91) and Number of IFN Sensitivity-Determining Region Mutations**

We measured pre-treatment factors such as prediction of clinical outcome of therapy, amino acid sequence variation in the NSSA region (referred to as IFN sensitivity-determining regions) and in the core protein regions (aa 70 and aa 91) of HCV with a given genotype, and the viral load.

**HCV RNA Measurement**

The quantity of HCV RNA was measured by real-time PCR (detection limit 1.2 log IU/ml), by HCV core antigen (detection limit 20 fmol/l), and by RT-PCR (Amplicor HCV monitor v 2.0; Roche; detection limit 50 IU/ml).

**Viral Reduction and Viral Response Rate**

The quantity of HCV RNA was converted to a log value at the beginning of the treatment (A) and at each of the virus measurement points (B). Δlog was then calculated: Δlog = logA – logB = log (A/B).

**Evaluation of DFPP Safety**

The subjective and objective adverse events of DFPP were observed, and five clinical factors were measured (platelet and lymphocyte counts, and hemoglobin, albumin and fibrinogen levels) before the first session of DFPP, before successive sessions on the second, third, fourth, fifth and sixth days, and 2 weeks after the last session.

**Statistical Analysis**

Statistical analysis consisted of analysis of variance for patient background factors, and the paired t test for quantities of HCV RNA at the second filter inlet during DFPP. The t test was used for viral load reductions and Fisher’s exact test for viral response rates among the groups. The t test was 2-tailed, and differences of p < 0.05 were considered significant.

Plasmapheresis plus IFN for Non-Responders to Previous Therapy
Results

Of the 9 patients, 1 was PR and 8 were NR. Virus mutation in the core region was as follows: wild type (7 patients) and mutant type (2 patients) at aa 70; wild type (6 patients) and mutant type (3 patients) at aa 91. IFN sensitivity-determining regions demonstrated mutation 1 (5 patients) and mutation 0 (4 patients), while mutation 2 was not seen in any patient. The overall viral dynamics of DFPP plus IFN treatment with or without RBV for 4 weeks showed a reduction in the viral load of $\geq 1\log$ in 22% (2 of 9 patients), 55.6% (5/9), 77.8% (7/9) and 77.8% (7/9) at 24 h, 1, 2 and 4 weeks after the start of treatment, respectively. The early viral dynamics after DFPP plus consecutive intravenous IFN-$\beta$ treatment for 4 weeks showed a reduction in the viral load of $\geq 1\log$ in 33% (2 of 6 patients), 50% (3/6), 83.3% (5/6) and 83.3% (5/6) at 24 h, 1, 2 and 4 weeks after the start of treatment, respectively. The reduction of the viral load by $\geq 2\log$ was observed in 50% (3 of 6 patients) at 4 weeks after the start of treatment (table 1).

Discussion

New drugs to replace IFN as well as drugs that can be used in combination with IFN are being actively developed. Also, attempts are being made to find ways to physically remove HCV particles from the blood. Granulocyte apheresis, plasma exchange and hemofiltration have been applied to HCV-infected patients for the treatment of cryoglobulinemia and vasculitis, modalities which have been shown to reduce HCV RNA in the blood during treatment [6–11]. The mechanisms of the clinical results of plasmapheresis have been described, whereby HCV in the blood is related to the effects of IFN therapy that could be enhanced by removing the virus from blood [12–14]. Low-density lipoprotein–cholesterol apheresis and plasma exchange in hypercholesteremic patients with HCV infection reduces the quantity of HCV RNA in the blood of some patients [15]. Hemodialysis, hemofiltration and peritoneal dialysis in chronic dialysis patients infected with HCV significantly lower HCV RNA levels in the blood [16]. Combined granulocyte apheresis with IFN therapy for CHC [17–19] and the prerequisite for early reduction of the virus in the treatment of CHC [20, 21] are essential. Thus, the potential effectiveness of IFN therapy combined with early physical removal of the virus is of particular interest.
Asahina et al. [22] studied HCV dynamics in both serum and peripheral blood mononuclear cells in 44 patients, with HCV genotype 1b and high viral loads, randomly assigned to 4 treatment groups: (1) combination therapy with 6 MU daily of IFNα-2b plus 800 mg of RBV; (2) monotherapy with 6 MU daily of IFNα-2b; (3) monotherapy with twice-daily intravenous administration of 3 MU of IFN-β, and (4) monotherapy with daily intravenous administration of 6 MU of IFN-β. HCV RNA levels measured serially by highly sensitive real-time PCR and HCV dynamics in both serum and peripheral blood mononuclear cells have demonstrated a ‘biphasic’ pattern. The exponential decay slopes of the second phase have been significantly higher in the combination or the twice-daily dose regimen groups than in group 2 or 4 (0.10 ± 0.08 vs. 0.02 ± 0.09 or 0.16 ± 0.09 vs. 0.02 ± 0.04 day⁻¹; p < 0.05 and p < 0.0005, respectively) [22]. Kim et al. [23] observed that a daily dose of IFN-β 6 MU for 4 weeks effects a 2 log decrease in the HCV RNA load in 7 patients with genotype 1b and high viral loads.

In this study, early viral dynamics were assessed in the 9 patients non-SVR to the combination therapy. The overall viral dynamics of DFPP plus IFN treatment with or without RBV for 4 weeks reduced the viral load by ≥1 log in 22% (2 of 9 patients), 55.6% (5/9), 77.8% (7/9), and 77.8% (7/9) at 24 h, 1, 2 and 4 weeks after the start of treatment, respectively. DFPP plus consecutive intravenous IFN-β treatment for 4 weeks reduced the viral load by ≥1 log in 33% (2/6), 50% (3/6), 83.3% (5/6) and 83.3% (5/6) at 24 h, 1, 2 and 4 weeks after the start of treatment, respectively.

The prerequisite for early virological response (EVR; indicating negative HCV RNA at 12 weeks) has been emphasized in predicting SVR and non-SVR in CHC patients undergoing IFN treatment; those who do not reach EVR fail to respond to further therapy. Treatment discontinued in patients not reaching EVR would reduce drug costs by more than 20%; consequently, early confirmation of viral reduction after initiating antiviral therapy for CHC is highly desirable [24].

To be able to predict SVR with PEG-IFN/RBV treatment, reduction of the HCV RNA viral load by week 4 is considered essential. A 2 log reduction in the HCV RNA viral load by week 4 is a prerequisite to achieving SVR with PEG-IFN/RBV treatment [25]. In our study of DFPP plus consecutive intravenous IFN-β treatment for 4 weeks, a reduction in the viral load of ≥2 log was achieved in 50% (3 of 6 patients) at 4 weeks after the start of treatment.

From the above considerations, DFPP plus consecutive intravenous IFN-β treatment for 4 weeks is a promising regimen for non-SVR patients with genotype 1b and high viral loads, previously treated with PEG-IFN/RBV therapy. Further study is needed to elucidate the SVR rate in a larger number of patients given DFPP plus IFN treatment, especially with consecutive interferon IFN-β.

Acknowledgment

We are indebted to Yoshiko Kawamura for assistance in the preparation of the manuscript.

Disclosure Statement

No conflict of interest exists.

References


